Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

50.66USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$50.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
790,059
52-wk High
$63.40
52-wk Low
$41.93

Breyer, Robert 

Mr. Robert A. Breyer is Independent Director of Alkermes Plc. Mr. Breyer served as the President of Alkermes, Inc. from July 1994 until his retirement in December 2001 and Chief Operating Officer from July 1994 to February 2001. Prior to that time, Mr. Breyer was an executive and held various positions in the global pharmaceutical and medical device industries, including general manager of Eli Lilly Benelux S.A and Eli Lilly Italia S.p.A. Mr. Breyer also served on the board of directors of Lentigen, Inc., a privately held, diversified biology company from 2007 to 2009. Mr. Breyer’s experience as an executive in the global pharmaceutical and medical device industries provides management and operational skills to our Board. Mr. Breyer has experience with managing the overall financial performance of pharmaceutical and medical device units and in pharmaceutical manufacturing and sales and marketing operations in multiple locations in the U.S. and Europe. As a former executive at Alkermes, Inc., Mr. Breyer also has first-hand knowledge of our technology, manufacturing operations, research and development and management team.

Basic Compensation

Total Annual Compensation, USD 96,500
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 423,986
Fiscal Year Total, USD 520,486

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

9,647,420

Shane Cooke

4,144,870

James Frates

2,678,060

Kathryn Biberstein

3,430,420

Elliot Ehrich

3,452,210

Iain Brown

--
As Of  30 Dec 2016